Ward D, Kalir A, Trevor A, Adams J, Baillie T, Castagnoli N. Metabolic formation of
iminium species: the metabolism of phencyclidine. J Med Chem 1982;25:491–492.
Welch KD, Wen B, Goodlett BR, Yi EC, Lee H, Reilly TP, Nelson SD, Pohl LR.
Proteomic identification of potential susceptibility factors in drug-induced liver
diseases. Chem Res Toxicol 2005;18:924–933.
Wen Z, Stern ST, Martin DE, Lee K-H, Smith PC. Structural characterization of anti-
HIV drug candidate PA-457 [3-O-(3^0 ,3^0 -dimethylsuccinyl)-betulinic acid] and its acyl
glucuronides in rat bile and evaluation ofin vitrostability in human and animal liver
microsomes and plasma. Drug Metab Dispos 2006;34:1436–1442.
Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical
carcinogenesis. Semin Cancer Biol 2004;14:473–486.
Yan Z, Caldwell GW. Stable-isotope trapping and high-throughput screenings of
reactive metabolites using the isotope MS signature. Anal Chem 2004;76:6835–6847.
Yang XX, Hu ZP, Chan SY, Zhou SF. Monitoring drug–protein interaction. Clin Chim
Acta 2006;365:9–29.
Zhang D, Ogan M, Gedamke R, Roongta V, Dai R, Zhu M, Rinehart JK, Klunk L,
Mitroka J. Protein covalent binding of maxipost through a cytochrome P450-
mediated orthoquinone methide intermediate in rats. Drug Metab Dispos
2003;31:837–845.
Zhang Z, Chen Q, Li Y, Doss GA, Dean BJ, Ngui JS, Elipe MS, Kim S, Wu JY,
DiNinno F, Hammond ML, Stearns RA, Evans DC, Baillie TA, Tang W. In vitro
bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by
cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium
and quinone-type metabolites. Chem Res Toxicol 2005;18:675–685.
Zhou S. Separation and detection methods for covalent drug–protein adducts. J
Chromatogr B 2003;797:63–90.
476 PROTOCOLS FOR ASSESSMENT